Back to Journals » Cancer Management and Research » Volume 11

Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel

Authors Viardot A, Wais V, Sala E, Koerper S

Received 18 December 2018

Accepted for publication 28 February 2019

Published 25 March 2019 Volume 2019:11 Pages 2393—2404

DOI https://doi.org/10.2147/CMAR.S163225

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun


Andreas Viardot,1 Verena Wais,1 Elisa Sala,1 Sixten Koerper2,3

1Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; 2Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany; 3Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

Abstract: Axicabtagene lisoleucel (Axi-cel) is the second approved gene-alterating cancer treatment and the first in aggressive lymphoma using the “chimeric antigen receptor” (CAR) technology. T-cells from patients were transfected with CARs and reinfused after a lymphodepleting chemotherapy. CAR T-cells are “living drugs” with the ability to persist and expand after a single infusion. Axi-cel is a “second generation” CAR product characterized by the use of a retroviral gene vector transfer and by CD28 as costimulatory domain. In a phase II trial with heavily pretreated patients with aggressive B-cell lymphoma, the overall response rate was 82% with an ongoing complete response rate of 40% after 6 months – with expectations of long-term remissions and cure, even though follow-up data are still limited. There are some prominent side effects like cytokine release syndrome (Grade 3–5: 13%) and neurotoxicity (Grade 3–5: 28%). Novel strategies for prediction, prevention and treatment of these critical side effects are warranted. There are new concepts to enhance the efficacy and prevent resistance in lymphomas. CAR T-cells represent an extremely evolving field with an inestimable potential in general and particularly in aggressive lymphoma. However, we are still learning how to use Axi-cel and other CAR-T cells compounds effectively to optimize the long-term results.

Keywords: chimeric antigen receptor, CAR T-cells, Axicabtagene ciloleucel, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, transformed follicular lymphoma, cytokine release syndrome, neurotoxicity, CAR related encephalopathy syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]